Claims for Patent: 8,293,883

✉ Email this page to a colleague

Summary for Patent: 8,293,883

Title:	Engineered anti-IL-23P19 antibodies
Abstract:	Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g., in treatment of inflammatory, autoimmune, and proliferative disorders.
Inventor(s):	Presta Leonard G.
Assignee:	Schering Corporation
Application Number:	US12526543
Patent Claims:

Details for Patent 8,293,883

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sun Pharmaceutical Industries Limited	ILUMYA	tildrakizumab-asmn	Injection	761067	March 20, 2018	8,293,883	2028-02-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,293,883

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
South Africa	200906224	⤷ Get Started Free
World Intellectual Property Organization (WIPO)	2008103432	⤷ Get Started Free
United States of America	9809648	⤷ Get Started Free
United States of America	8404813	⤷ Get Started Free
United States of America	2013122009	⤷ Get Started Free
United States of America	2011142853	⤷ Get Started Free
United States of America	2010272731	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.